Compugen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Compugen şirketinin toplam hissedar öz sermayesi $60.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $123.5M ve $63.0M dir. Compugen 'in FAVÖK'ü $10.6M faiz karşılama oranı -2.5 dur. Şirketin $112.7M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-2.5x
Nakit	US$112.71m
Eşitlik	US$60.49m
Toplam yükümlülükler	US$63.03m
Toplam varlıklar	US$123.52m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CGEN 'nin kısa vadeli varlıkları ( $114.8M ) kısa vadeli yükümlülüklerini ( $27.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: CGEN şirketinin kısa vadeli varlıkları ( $114.8M ) uzun vadeli yükümlülüklerini ( $35.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CGEN borçsuzdur.

Borcun Azaltılması: CGEN son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: CGEN un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: CGEN şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Compugen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Compugen Announces Receipt of Nasdaq Delisting Notice

Recent updates

Forecast to breakeven in 2024

Compugen Ltd. to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen Ltd. to Report Q3, 2024 Results on Nov 12, 2024

New minor risk - Profitability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2025

Compugen Ltd., Annual General Meeting, Sep 12, 2024

Compugen Ltd. Announces FDA Clearance of IND for Com503 for the Treatment of Solid Tumors

Compugen Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Compugen Ltd. Announces CFO Changes, Effective August 15, 2024

Compugen Ltd. to Report Q1, 2024 Results on May 20, 2024

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Now 20% undervalued

Compugen Ltd. to Report Q4, 2023 Results on Mar 05, 2024

Compugen Ltd. Announces Executive Changes

New major risk - Revenue and earnings growth

New major risk - Share price stability

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer

Compugen Ltd. to Report Q3, 2023 Results on Nov 07, 2023

Insufficient new directors

New major risk - Revenue and earnings growth

Compugen Ltd., Annual General Meeting, Sep 20, 2023

Compugen Ltd. to Report Q2, 2023 Results on Aug 07, 2023

Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Compugen Ltd. to Report Q4, 2022 Results on Feb 27, 2023

Compugen Ltd.'s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

Compugen Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

Compugen Announces Receipt of Nasdaq Delisting Notice

Compugen Ltd. to Report Q3, 2022 Results on Nov 14, 2022

Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer

Compugen Ltd. Announces Resignation of Ari Krashin as Chief Operating Officer in August 2022

Compugen Ltd. to Report Q2, 2022 Results on Aug 04, 2022

Compugen Announces CFO Departure

Compugen Ltd. to Report Q1, 2022 Results on May 16, 2022

Compugen Ltd. Announces Board Changes

Compugen Ltd. to Report Q4, 2021 Results on Feb 24, 2022

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

High number of new directors

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

Compugen Ltd. Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

Compugen Ltd. Updates Data from Phase 1 Study of COM701

Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy

Revenue in line with expectations

Compugen Ltd. Announces Data Update from Com701 Phase 1 Clinical Trial

Compugen Ltd. Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®

New 90-day low: ₪33.90

Compugen Ltd. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day low: ₪38.90

New 90-day low: ₪39.28

Compugen Ltd. Announces Progress from Its Ongoing License Agreement with Astrazeneca

New 90-day low: ₪41.40

New 90-day low: ₪42.84

New 90-day low: ₪47.47

Compugen Ltd. Announces Board Changes

New 90-day high - ₪60.69

Compugen Ltd. to Report Q2, 2020 Results on Jul 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin